Mes-Masson AM - Search Results

1

The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.

Wojnarowicz PM, Oros KK, Quinn MC, Arcand SL, Gambaro K, Madore J, Birch AH, de Ladurantaye M, Rahimi K, Provencher DM, Mes-Masson AM, Greenwood CM, Tonin PN. Wojnarowicz PM, et al. PLoS One. 2012;7(9):e45484. doi: 10.1371/journal.pone.0045484. Epub 2012 Sep 20. PLoS One. 2012. PMID: 23029043 Free PMC article.

2

Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies.

Lounis H, Provencher D, Godbout C, Fink D, Milot MJ, Mes-Masson AM. Lounis H, et al. Exp Cell Res. 1994 Dec;215(2):303-9. doi: 10.1006/excr.1994.1346. Exp Cell Res. 1994. PMID: 7526992

3

Absence of human papillomavirus sequences in ovarian pathologies.

Trottier AM, Provencher D, Mes-Masson AM, Vauclair R, Coutlée F. Trottier AM, et al. J Clin Microbiol. 1995 Apr;33(4):1011-3. doi: 10.1128/jcm.33.4.1011-1013.1995. J Clin Microbiol. 1995. PMID: 7790425 Free PMC article.

4

Discordance in p53 mutations when comparing ascites and solid tumors from patients with serous ovarian cancer.

Provencher DM, Lounis H, Fink D, Drouin P, Mes-Masson AM. Provencher DM, et al. Tumour Biol. 1997;18(3):167-74. doi: 10.1159/000218027. Tumour Biol. 1997. PMID: 9143413

5

Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study.

Godard B, Foulkes WD, Provencher D, Brunet JS, Tonin PN, Mes-Masson AM, Narod SA, Ghadirian P. Godard B, et al. Am J Obstet Gynecol. 1998 Aug;179(2):403-10. doi: 10.1016/s0002-9378(98)70372-2. Am J Obstet Gynecol. 1998. PMID: 9731846

6

Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.

Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DE, Provencher D, Ghadirian P, Narod SA. Tonin PN, et al. Am J Hum Genet. 1998 Nov;63(5):1341-51. doi: 10.1086/302099. Am J Hum Genet. 1998. PMID: 9792861 Free PMC article.

7

Mapping of chromosome 3p deletions in human epithelial ovarian tumors.

Lounis H, Mes-Masson AM, Dion F, Bradley WE, Seymour RJ, Provencher D, Tonin PN. Lounis H, et al. Oncogene. 1998 Nov 5;17(18):2359-65. doi: 10.1038/sj.onc.1202152. Oncogene. 1998. PMID: 9811467

8

Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites.

Manning AP, Mes-Masson AM, Seymour RJ, Tetrault M, Provencher DM, Tonin PN. Manning AP, et al. Mol Carcinog. 1999 Mar;24(3):218-25. doi: 10.1002/(sici)1098-2744(199903)24:3<218::aid-mc8>3.0.co;2-a. Mol Carcinog. 1999. PMID: 10204806

9

Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history.

Tonin PN, Mes-Masson AM, Narod SA, Ghadirian P, Provencher D. Tonin PN, et al. Clin Genet. 1999 May;55(5):318-24. doi: 10.1034/j.1399-0004.1999.550504.x. Clin Genet. 1999. PMID: 10422801

10

Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers.

Dion F, Mes-Masson AM, Seymour RJ, Provencher D, Tonin PN. Dion F, et al. Oncogene. 2000 Mar 9;19(11):1466-72. doi: 10.1038/sj.onc.1203463. Oncogene. 2000. PMID: 10723138

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

327 results

Search Page

Filters